Author

L. Tonon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 5 Organism:human· 5 Assay:bulk RNA-seq· 4 Approach:experimental assay· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:biophysical modeling· 1

Frequent Co-Authors

C. Degletagne· 3 shared A. Puisieux· 2 shared A.-P. Morel· 2 shared C. Caux· 2 shared M. Ardin· 2 shared M. Ouzounova· 2 shared M.-C. Michallet· 2 shared A. Boman· 1 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Degletagne

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Spatial transcriptomics reveal pitfalls and opportunities for the detection of rare high-plasticity breast cancer subtypes

A. Coutant, V. Cockenpot, L. Muller, C. Degletagne, R. Pommier, L. Tonon, M. Ardin, M.-C. Michallet, C. Caux, M. Laurent, A.-P. Morel, P. Saintigny, A. Puisieux, M. Ouzounova, P. Martinez

The paper uses spatial transcriptomics to identify specific markers for rare high-plasticity breast cancer subtypes, showing that bulk expression signatures are limited by stromal contamination.

bioRxiv · Apr 24, 2023Cancer Biology

A Unique Polyfunctional IL-33-responsive ST2⁺ NK cell State Potentiates Antitumor Immunity and Response to Immunotherapy

A. Eberhardt, E. Blanc, V. Picant, A. Voissiere, L. Revol-Bauz, T. Casini, V. Alcazer, D. Poujol, L. Tonon, R. Schneider, E. Picard, Y. Rocca, M. Ardin, F. Onodi, C. Degletagne, , N. Bendriss-Vermare

The paper identifies a unique ST2+ NK cell state that enhances antitumor immunity and response to immunotherapy through IL-33 and IL-12 signaling.

bioRxiv · Feb 14, 2023 · PreprintCancer Biology

Fusion-negative Rhabdomyosarcoma 3D-organoids as an innovative model to predict resistance to cell death inducers

C. Savary, P. Huchede, L. Luciana, A. Tourbez, C. Deligne, C. Picard, T. Diot, C. Coquet, N. Meynard, M. Le Grand, L. Tonon, N. Gadot, C. Degletagne, S. Leon, V. Attignon, , L. Broutier

The paper develops a 3D-organoid model of fusion-negative rhabdomyosarcoma to predict resistance to cell death inducers using omics data.

bioRxiv · Sep 6, 2022 · PreprintCancer Biology

RAS-induced transformation of mammary epithelial cells relies on ZEB1-dependent cellular reprogramming via a paracrine process

H. De Blander, L. Tonon, F. Fauvet, R. M. Pommier, C. Lamblot, R. Benhassoun, F. Angileri, B. Gibert, M. Ouzounova, A.-P. Morel, A. Puisieux

This study shows RAS-induced transformation of mammary epithelial cells depends on ZEB1-dependent reprogramming via a paracrine process involving senescent cell-derived cytokines.

bioRxiv · Jun 23, 2022 · PreprintCancer Biology

Hepatocellular carcinoma hosts immature neurons and cholinergic tumors that correlate with adverse molecular features and outcomes

C. A. Hernandez, C. Verzeroli, I. Chicherova, A.-J. Farca-Luna, L. Tonon, P. Bellaud, B. Turlin, A. Fautrel, Z. Macek-Jilkova, T. Decaens, S. Rebouissou, A. Viari, F. Zoulim, R. Parent

This study identifies neural features in hepatocellular carcinoma, showing cholinergic tumors correlate with adverse molecular traits and worse outcomes.

bioRxiv · Jun 14, 2022 · PreprintCancer Biology